跳到正文
原文
Medical Xpress·· 10 天前精选AI 评分75

静脉抗血小板药物可能改善心脏病发作并发心源性休克患者的的心脏功能

Intravenous antiplatelet therapy may improve heart function in cardiogenic shock patients compared to oral medication

AI 导读

一项由Mount Sinai研究人员领导的随机对照试验显示,静脉注射cangrelor在心脏病发作并发心源性休克患者中比口服ticagrelor更能改善心脏功能。cangrelor组患者心脏左室射血分数提高37.9%,而ticagrelor组仅提高21.7%。研究还发现cangrelor能显著降低微血管阻塞的风险。

推荐理由

研究显示静脉抗血小板药物在心脏病发作并发心源性休克患者中优于口服药物,有助于改善心脏功能。

正文 · 原文
blood
Credit: Pixabay/CC0 Public Domain

Patients who survive cardiogenic shock after a heart attack are among the highest-risk patients and have a significant risk of developing heart failure. Any improvement of heart function should reduce their risk of developing heart failure in the long term.

A trial led by Mount Sinai researchers demonstrates the potential benefit of powerful intravenous blood thinners (antiplatelet drugs) in reducing complications in these complex cases. For heart attack patients who develop cardiogenic shock—the most serious complication of a heart attack—cangrelor, a potent intravenous blood thinner, resulted in better recovery of heart function when compared to oral antiplatelet therapy. The findings are published in The Lancet journal.

This is the first randomized trial of double antiplatelet therapy in heart attacks complicated by cardiogenic shock.

Cangrelor delivers stronger platelet inhibition

Researchers randomized 605 patients who underwent cardiac stent procedures. Before the procedure, 298 were given cangrelor and 307 were given crushed ticagrelor, an oral antiplatelet medication. The researchers wanted to see how well the two different drugs stopped blood from clotting.

The primary laboratory endpoint of platelet reactivity index of less than 50% (the benchmark doctors use to prove blood thinners are effectively working) was analyzed in 56 patients from the cangrelor group and 68 from the ticagrelor group. This benchmark was achieved in 100% of patients in the cangrelor group and 22% in the ticagrelor group.

Less vessel obstruction, greater heart recovery

In the imaging substudy, cangrelor was much better at protecting the heart from microvascular obstruction. In this phenomenon, small fragments of plaque or clots break off and plug up blood vessels in the heart, which can damage the heart muscle. Patients who took cangrelor had a 73% lower chance of developing this dangerous complication than patients on ticagrelor.

After one year, cangrelor patients saw a much bigger increase in their heart's left ventricular ejection fraction (a measure of the heart's pumping ability) compared to patients on ticagrelor. Ultrasounds showed a 37.9% improvement compared to ticagrelor's 21.7%, and MRIs showed a 15.8% increase for the cangrelor group compared to 2.1% on ticagrelor.

Long-term prognosis remains under study

Cardiogenic shock after a heart attack is fatal by a year in about half of patients. Use of potent blood thinners at the time of stenting may improve that grim prognosis and improve outcomes in cardiogenic shock. This is an important finding considering that no therapies other than prompt revascularization of the blocked vessel or mechanical heart pumps have ever been shown to be effective for cardiogenic shock.

Long-term follow-up of DAPT-SHOCK-AMI is ongoing and should help teach researchers about the long-term prognosis of patients with acute myocardial infarction who develop cardiogenic shock and survive the initial event. Conducting larger, randomized trials on this subject may help further advance treatment; however, conducting these could be difficult, as these patients are the sickest of the sick.

"This is the largest randomized trial of antiplatelet strategies in cardiogenic shock to date. Our findings should help inform the design of future trials in this difficult-to-study population," said senior and corresponding author, Deepak L. Bhatt.

"Beyond the findings regarding cangrelor, this trial establishes the value of serial echocardiography and MRI in characterizing recovery from cardiogenic shock, one of the most lethal conditions in medicine. Future studies can use the approaches we studied here to evaluate novel therapies for cardiogenic shock."

Publication details

Zuzana Motovska et al., Cangrelor versus crushed ticagrelor in acute myocardial infarction complicated by cardiogenic shock (DAPT-SHOCK-AMI): a randomised, double-blind trial, The Lancet (2026). DOI: 10.1016/s0140-6736(26)00976-1

Journal information: The Lancet

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Intravenous antiplatelet therapy may improve heart function in cardiogenic shock patients compared to oral medication (2026, November 9) retrieved 9 November 2026 from https://medicalxpress.com/news/2026-11-intravenous-antiplatelet-therapy-heart-function.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com